Phase III clinical trial testing Bavencio (Pfizer, Merck KGaA) on ovarian carcinoma fails

Pfizer and its partner Merck KGaA have jointly announced today that the Phase III Javelin Ovarian 200 clinical trial has not delivered the expected results. Specifically, the trial has shown that immunotherapy Bavencio(avelumab), combined to chemotherapy (pegylated liposomal doxorubicin) or as monotherapy, has failed to cure ovarian carcinoma and has not met its primary endpoints. The two companies have provided no update about their other ongoing clinical trial Javelin Ovarian 100, assessing avelumab in combination with chemotherapy, followed by a maintenance treatment with avelumab combined to a PARP inhibitor.

(Source: Pfizer)